Sanofi conference spotlights type 2 inflammations

Dr. Ahmed Siraj, general manager of Sanofi Saudi Arabia, spoke at the conference held in Jeddah Hilton.

Global health care company Sanofi recently organized a medical conference on type 2 inflammations, namely atopic dermatitis and severe asthma, at the Jeddah Hilton. The event, held under the auspices of the Saudi Allergy, Asthma and Immunology Society, included speakers from various health sectors who highlighted latest technologies and Saudi Food and Drug Authority-approved medicines to treat the diseases.
In his opening speech, Professor Abdullah Al-Angari, president of the Saudi Allergy, Asthma and Immunology Society, praised the society’s keenness to organize such important conferences to review the latest developments in type 2 inflammations, and to attract specialists from around the globe. “The scientific papers presented at the conference contribute to informing about the latest developments in treating these diseases. Sanofi Dupixent medication plays an important role in the treatment of the second type of immune inflammations, which include atopic dermatitis and severe asthma. The Kingdom of Saudi Arabia is among the few countries around the world that provide such a treatment for this disease,” he added.
Dr. Ahmed Siraj, general manager of Sanofi Saudi Arabia, said: “It is of utmost importance to develop cooperation between specialized Arab and international societies by exchanging experiences and knowledge and the latest developments in the treatment of the type 2 immune Inflammations, and the need to hold training courses for beginner Saudi doctors to hone their skills. The disease has several remarkable features, including its genetic aspects and family roots, its signs that include dry skin, allergy toward special types of food, sensitivity to exposure to dust and weather changes, etc., all of which must be taken into consideration when treating the disease.”
The two-day conference covered various topics, including the relationship between basic immunology and allergies, difficulties in dealing with type 2 immune inflammations, and the role of immune cells in disease and clinical trials, among others. Some local experiences with new Sanofi Biologic were also reviewed. The conference highlighted the best practices of treating type 2 immune inflammations from Canada and Saudi Arabia, where Professor Jason Lee conveyed the Canadian experience of immune diseases to the attendees.